Amir Alam Hospital Complexes, Tehran University of Medical Sciences, Sa'adi Street, Tehran, Iran.
Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, Tehran, Iran.
BMC Res Notes. 2021 Jul 23;14(1):283. doi: 10.1186/s13104-021-05700-x.
The purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine.
In this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migraine patients than when W-3 is administered alone.
This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: NCT02532023.
本临床试验旨在研究 ω-3 脂肪酸（W-3 FAs）、纳米姜黄素及其联合应用对发作性偏头痛患者血清 VCAM 水平和基因表达的影响。
本研究将 80 例患者随机分为 4 组，接受治疗 2 个月。单独使用 W-3 以及联合使用 W-3 和纳米姜黄素干预后，血清 VCAM 水平和基因表达均显著下降。然而，单独使用纳米姜黄素补充剂和对照组分别观察到边缘显著变化和无明显变化。虽然研究组之间在 VCAM 浓度方面存在显著差异，但各组之间 VCAM 基因表达无显著差异。W-3 和联合 W-3 和纳米姜黄素可缓解发作性偏头痛患者的 VCAM 血清水平及其基因表达。此外，与单独使用 W-3 相比，W-3 与纳米姜黄素联合使用可能导致偏头痛患者血清中 VCAM 水平的显著下降。
本研究在伊朗临床试验注册中心（IRCT）注册，注册号为：NCT02532023。
